1

Adaptimmune Therapeutics

#10094

Rank

$21.18M

Marketcap

GB United Kingdom

Country

Adaptimmune Therapeutics
Leadership team

Mr. Adrian G. Rawcliffe (CEO, Principal Accounting Officer & Director)

Dr. Helen Katrina Tayton-Martin MBA, Ph.D. (Co-Founder & Chief Bus. & Strategy Officer)

Mr. Gavin Hilary James Wood BA (Hons), ACA (Chief Financial Officer)

Products/ Services
Biopharma, Biotechnology, Health Care, Medical
Number of Employees
100 - 500
Headquarters
Oxton, York, United Kingdom
Established
2008
Company Registration
SEC CIK number: 0001621227
Revenue
5M - 20M
Traded as
ADAP
Social Media
Overview
Location
Summary
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
History

Adaptimmune was founded in 2008, launching one of the first clinical trials to test the safety of an approach known as TCR-T therapy. TCR-T therapy involves taking T-cells from a patient’s blood, genetically engineering them to recognize cancer cells, and infusing them back into the patient. Adaptimmune’s breakthroughs over the past decade have proven the efficacy of their approach, and the company is now working to improve the capabilities of their therapies, with the goal of becoming an industry leader in T-cell therapy for cancer treatments.

Mission
Adaptimmune’s mission is to apply our deep expertise in immunotherapy to unleash the power of the immune system to treat cancer and save patients’ lives.
Vision
Adaptimmune’s vision is to be the preeminent T-cell therapy company, providing life-saving treatments to cancer patients.
Key Team

Mr. William C. Bertrand Jr., Esq., J.D. (Chief Operating Officer)

Mr. John Lunger (Chief Patient Supply Officer)

Ms. Joanna Brewer Ph.D. (Chief Scientific Officer)

Dr. Juli P. Miller Ph.D. (VP of Investor Relations)

Ms. Kerry Sharp (Sr. VP & Gen. Council)

Ms. Margaret Henry (Head of PR & Company Sec.)

Mr. Sébastien Desprez (VP of Communications & Corp. Affairs)

Recognition and Awards
Adaptimmune has won numerous awards, including the prestigious Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation in 2011, and the Fast Track Award from the National Institutes of Health in 2013.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Adaptimmune Therapeutics
Leadership team

Mr. Adrian G. Rawcliffe (CEO, Principal Accounting Officer & Director)

Dr. Helen Katrina Tayton-Martin MBA, Ph.D. (Co-Founder & Chief Bus. & Strategy Officer)

Mr. Gavin Hilary James Wood BA (Hons), ACA (Chief Financial Officer)

Products/ Services
Biopharma, Biotechnology, Health Care, Medical
Number of Employees
100 - 500
Headquarters
Oxton, York, United Kingdom
Established
2008
Company Registration
SEC CIK number: 0001621227
Revenue
5M - 20M
Traded as
ADAP
Social Media